Fennec Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes therapies to prevent cisplatin-induced ototoxicity, a serious and often irreversible hearing loss caused by cancer treatment. The company's core product is PEDMARK® (sodium thiosulfate injection), the first and only FDA-approved therapy indicated to reduce the risk of hearing loss in pediatric patients receiving cisplatin for solid tumors, which demonstrated approximately 50% relative reduction in ototoxicity incidence in clinical studies. Fennec generates revenue through direct product sales in the United States via a field force of pediatric oncology specialists and patient support programs, and through licensing agreements in international territories that provide upfront payments, milestone payments, and royalties on net sales.